FDA approval of investigational drugs is a significant positive development for pharmaceutical companies, often leading to increased investor confidence and potential stock price appreciation. Given that OK-101 is targeting a specific and potentially underserved market (neuropathic corneal pain), this approval positions Okyo Pharma favorably in the biotech and healthcare sectors. The anticipation of clinical trials beginning in Q2 2024 further solidifies the company's pipeline progress.